Figure 1From: Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study)Flow of patients through the study. *No evidence of intake of study drug; †Patients that discontinued the study due to adverse events underwent the final visit and were included in the ITT population.Back to article page